Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.67 USD
−97.40 M USD
0.00 USD
36.90 M
About Oculis Holding AG
Sector
Industry
CEO
Riad Sherif
Website
Headquarters
Zug
Founded
2016
ISIN
CH1246223429
FIGI
BBG01FQKCZ10
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.
Displays a symbol's price movements over previous years to identify recurring trends.